Showing 1541-1550 of 5771 results for "".
- Vision Expo East Announces Keynote Speakerhttps://modernod.com/news/vision-expo-east-announces-keynote-speaker/2481419/Vision Expo East announced that Jason Romero, a legally blind ultra-runner, will be the keynote speaker at the annual conference in New York City from March 16-19, 2023 (Education opens March 16; Exhibits open March 17). “After losing his vision to a dege
- Celanese Announces a Research Agreement with Johns Hopkins University to Advance Sustained Ocular Drug Delivery to the Suprachoroidal Spacehttps://modernod.com/news/celanese-announces-a-research-agreement-with-johns-hopkins-university-to-advance-sustained-ocular-drug-delivery-to-the-suprachoroidal-space/2481417/Specialty materials and chemical company Celanese announced an agreement with Johns Hopkins University Department of Ophthalmology to collaborate on a study of sustained drug delivery to the suprachoroidal space in the eye. A bioinert implant based on the Celanese's VitalD
- Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetingshttps://modernod.com/news/ocuphire-announces-apx3330-phase-2-data-presentations-at-retina-meetings/2481416/Ocuphire Pharma announced two presentations featuring efficacy and safety results from the company’s recently completed ZETA-1 phase 2 trial of oral APX3330 in diabetic retinopathy (DR) at two medical meetings in February. Peter Kaiser, MD, Professor of Ophthalmology at the C
- Aura Biosciences Announces Positive Interim Phase 2 Data of Belzupacap Sarotalocan for Treatment of Early-Stage Choroidal Melanomahttps://modernod.com/news/aura-biosciences-announces-positive-interim-phase-2-data-of-belzupacap-sarotalocan-for-treatment-of-early-stage-choroidal-melanoma/2481414/Aura Biosciences announced the presentation of positive interim phase 2 safety and efficacy data of belzupacap sarotalocan (bel-sar) with an average of 9 months of follow up evaluating two key clinical endpoints: tumor control, and visual acuity preservation using the suprachoroidal (SC) rou
- GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from Phase 1/2 Trial of Optogenetic Treatment Candidate for RPhttps://modernod.com/news/gensight-biologics-announces-1-year-safety-data-and-efficacy-signals-from-phase-12-trial-of-optogenetic-treatment-candidate-for-rp/2481413/GenSight Biologics announced favorable safety data and encouraging efficacy signals at 1 year post-gene therapy administration for the PIONEER phase 1/2 clinical trial evaluating GS030 for the treatment of retinitis pigmentosa (RP) in 9 patients, with a follow-up up to 4 years (n=1).
- Eyenovia Announces Development Collaboration with Formosa Pharmaceuticalshttps://modernod.com/news/eyenovia-announces-development-collaboration-with-formosa-pharmaceuticals/2481412/Eyenovia announced that the company has entered into a development collaboration agreement with Taiwan-based Formosa Pharmaceuticals that seeks to combine Eyenovia’s Optejet dispensing technology with Formosa’s APNT nanoparticle formulation platform for the potential develop
- Ocular Therapeutix Announces Interim Data from the Ongoing US Phase 1 Trial Evaluating OTX-TKI for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-interim-data-from-the-ongoing-us-phase-1-trial-evaluating-otx-tki-for-the-treatment-of-wet-amd/2481406/Ocular Therapeutix announced interim 10-month data from its US phase 1 clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseas
- RxSight Announces Pricing of Public Offering of Common Stockhttps://modernod.com/news/rxsight-announces-pricing-of-public-offering-of-common-stock/2481395/RxSight, maker of the RxSight Light Adjustable Lens system, announced it has priced its underwritten public offering. RxSight expects to sell 4 million shares of its common stock at a price to the public of $12.50 per share. RxSight has granted the underwriter a 30-day op
- Orbis Announces 3-Year Partnership with Hoya Vision Carehttps://modernod.com/news/orbis-announces-3-year-partnership-with-hoya-vision-care/2481389/Eye care nonprofit Orbis International announced a renewed partnership with Hoya, which will commit its support over the next 3 years with a focus on helping school children get access to eye care in low- to middle-income countries, and on training eye care professionals around the world thr
- Clearside Biomedical Announces Leadership Changeshttps://modernod.com/news/clearside-biomedical-announces-leadership-changes/2481386/Clearside Biomedical announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, MD, will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ci